Abstract
Objectives Vitamin D supplementation has been proposed for the prevention and treatment of COVID-19, but the relationship between the two is inconclusive: Reduced serum vitamin D may predispose to COVID-19, but it may also be a secondary consequence of infection. The objective of this study was to assess the temporal association between serum vitamin D levels and COVID-19.
Design A single-institution case-control study and a historical cohort study
Setting University of California San Diego (UCSD) Health System in San Diego, California
Participants Patients testing positive for COVID-19 from January 1, 2020 to September 30, 2020 with serum 25-hydroxy-vitamin D (25(OH)D) measured within 180 days of diagnosis. Patients were separated based on whether 25(OH)D was measured before (n=107; “pre-diagnosis”) or after (n=203; “post-diagnosis”) COVID-19 diagnosis. Subjects with 25(OH)D assessments prior to COVID-19 diagnosis were evaluated using a case-control study design, while subjects with 25(OH)D measured after COVID-19 diagnosis were analyzed with a historical cohort study design.
Primary and Secondary Outcome Measures In the pre-diagnosis study, a conditional logistic regression was performed using COVID-19 infection status as the binary dependent variable. In the post-diagnosis study, an ordinary least squares regression was performed using serum 25(OH)D levels as the continuous dependent variable.
Results Serum 25(OH)D levels were not associated with the odds of subsequently testing positive for COVID-19 (OR 1.00, 95% CI: 0.98 to 1.02, p = 0.982). However, COVID-19 positive individuals had serum 25(OH)D measurements that were lower by 2.70 ng/mL (95% CI: −5.19 to −0.20, p = 0.034) compared to controls.
Conclusions In our study population, serum 25(OH)D levels were not associated with risk of testing positive for COVID-19 but were reduced in subjects after being diagnosed with COVID-19 infection. These results raise the possibility that reduced serum 25(OH)D may be a consequence and not a cause of COVID-19 infection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the UC San Diego Office of Research Affairs. Award/grant number is not applicable.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UCSD Institutional Review Board (protocol #200768) approved this study and approved a waiver for informed consent based on the requirements outlined in the Code of Federal Regulations on the Protection of Human Subjects (45 CFR 46). All data collection and analysis were performed in accordance with relevant guidelines and regulations.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets for this study are not publicly published due to presence of potential patient- identifiable information but will be made available from the corresponding author on reasonable request.
